戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 echnical challenges to developing successful cell therapy.
2 eta, suggesting a novel approach to adoptive cell therapy.
3 rucial role of cell dose in the responses to cell therapy.
4 ies such as checkpoint blockade and adoptive cell therapy.
5 peutic benefits associated with CD34(+) stem cell therapy.
6 of cardiac functions similar to cardiac stem cell therapy.
7 orably condition CD8(+) T cells for adoptive cell therapy.
8 eceived chimeric antigen receptor-modified T cell therapy.
9 urs in many autoimmune patients after anti-B cell therapy.
10 s in vascular research, drug development and cell therapy.
11  a modest benefit in patients receiving stem cell therapy.
12 CRS and other adverse events following CAR T-cell therapy.
13 nciple for therapeutic cloning combined with cell therapy.
14 ial translational significance in adoptive T-cell therapy.
15 for 7.5 months after the initiation of CAR T-cell therapy.
16 erentiation of grafted cells during neonatal cell therapy.
17 studies were safety and tolerability of this cell therapy.
18 showed significant functional improvement by cell therapy.
19 s as an alternative to hepatocytes for liver cell therapy.
20 s contribute to the limited efficacy of stem cell therapy.
21 create cells that are ideal for personalized cell therapy.
22  refractory MLL-B-ALL who receive CD19 CAR-T-cell therapy.
23 derived neural cells in disease modeling and cell therapy.
24 on who would likely benefit from adoptive NK-cell therapy.
25 cytes (CMs) are a promising tool for cardiac cell therapy.
26 etes also impairs reparative responses after cell therapy.
27 onjugate vaccines, bispecific antibodies and cell therapy.
28 anslatable genetic modification strategy for cell therapy.
29 umulation in tumors in a model of adoptive T cell therapy.
30 nts with ischemic heart disease treated with cell therapy.
31 an important step in clinical development of cell therapy.
32 uses on their potential role as new tool for cell therapy.
33 a practical approach to improving SHED-based cell therapy.
34 cently, to investigations of stem/progenitor cell therapy.
35 ransduced, making them viable candidates for cell therapy.
36 ential step to obtain effective products for cell therapy.
37 n of more effective protocols for adoptive T-cell therapy.
38 te safer application of effective CD19 CAR T-cell therapy.
39 oactive infusions a median of 5 days after T cell therapy.
40 al approach for restoring hair cells is stem cell therapy.
41 t of PIRI including CLI with or without stem cell therapy.
42 through genetics and the development of stem-cell therapy.
43 e after chimeric antigen receptor-modified T cell therapy.
44 vival and rejection in preclinical models of cell therapy.
45 l cancer after tumor-infiltrating adoptive T cell therapy.
46 nsion, rest pain, and walking capacity after cell therapy.
47 ticular in organ transplantation and in stem cell therapy.
48 it expected therapeutic benefits of adoptive cell therapy.
49 enome engineering to enhance next-generation cell therapies.
50  for the development of future clinical stem cell therapies.
51 is easily scalable in contrast to adoptive T-cell therapies.
52  lines, which would compromise their use for cell therapies.
53 J-64041757), and chimeric antigen receptor T-cell therapies.
54 elium holds promise for potential autologous cell therapies.
55 uromodulation and experimental gene and stem cell therapies.
56 ent advances opens the way for improved MPhi cell therapies.
57 trials and inform the design of future CAR T cell therapies.
58  strategy for improving the potency of CAR T cell therapies.
59 pporting the feasibility of autologous liver cell therapies.
60 ing of optic neuropathies and development of cell therapies.
61  can potentially be used in autologous liver cell therapies.
62 ckpoint inhibitors, vaccines, and adoptive T-cell therapies.
63 f soluble mediators in the context of immune cell therapies.
64 ll receptor targets in innovative adoptive T cell therapies.
65  development of stem-cell-based engineered T cell therapies.
66 ation design of receptors used in adoptive T cell therapies.
67  offers a promising strategy for making stem cell therapy a clinical reality.
68   Despite the promising efficacy of adoptive cell therapies (ACT) in melanoma, complete response rate
69                                     Adoptive cell therapy (ACT) trials to date have focused on transf
70                                   Adoptive T cell therapy (ACT) with antitumor CTL is a promising and
71  from PD-1(+) TILs can be used in adoptive T-cell therapy (ACT).
72 epletion enhances the efficacy of adoptive T cell therapy (ACT).
73                       Discovery of effective cell therapies against cancer can be accelerated by the
74 lations of engineered T cells for adoptive T-cell therapies and enable in vivo tracking and retrieval
75 fforts to improve the efficacy of adoptive T-cell therapies and immune checkpoint therapies in myelog
76 bes enable quantitative in vivo detection of cell therapies and inflammatory cells.
77 e approaches to enhance the efficacy of stem cell therapies and to overcome issues with cell therapy
78   New avenues of exploration include cardiac cell therapy and cellular reprogramming targeting cell d
79 e reported weighted mean differences between cell therapy and control groups.
80 tes (hPSC-CMs) constrains their potential in cell therapy and drug testing.
81   It has also pioneered the concepts of stem cell therapy and immunotherapy as a tool against cancer.
82 nterfere with immune cells used for adoptive cell therapy and may limit expected therapeutic benefits
83 s that potentially limit mutation-specific T-cell therapy and may require high-avidity TCRs that are
84 SCs) are among the major stem cells used for cell therapy and regenerative medicine.
85  T cells enhances the efficacy of adoptive T cell therapy and suggests a new therapeutic strategy for
86 pecific intracellular antigens without using cell therapy and suggests that epitope spreading could c
87 al trials, clarifying the perception of stem cell therapy and the risks of bone marrow harvest, and d
88 el substrates for cell culture applications, cell therapy and tissue engineering.
89 itive ion channels in the heart (via gene or cell therapy) and illumination of the cardiac surfaces (
90 erapeutic success in the field of hMSC-based cell therapy, and an optimal approach for hMSC-based cel
91 TCR/CD3, as a cornerstone compound in anti-T-cell therapy, and anti-TNF-alpha, as the most prominent
92 nsitive sensing, disease diagnostics, cancer cell therapy, and molecular computers.
93 logic feature can be exploited in allogeneic cell therapy, and the recognition of "missing-self" on t
94 toxic effector functions of TCM for adoptive cell therapy applications.
95 reg cell-mediated suppression and a new Treg cell therapy approach.
96                                An issue with cell therapy approaches to restore dystrophin expression
97 a source of cells for tissue engineering and cell therapy approaches.
98 for the development of successful autologous cell therapy approaches.
99                                            T-cell therapies are a promising approach for treating MM,
100 r, the underlying mechanisms of iPSC-derived cell therapy are still unclear, and limited engraftment
101 ing results for HSCT and mesenchymal stromal cell therapy as alternatives to systemic therapies and a
102 illustrate the potential use of SLAMF7-CAR T-cell therapy as an effective treatment against multiple
103 the potential clinical benefit of adoptive T-cell therapy (ATCT) of CMV phosphoprotein 65 (pp65)-spec
104                                   Adoptive T cell therapy (ATT) can achieve regression of large tumor
105 ajority of T cells suboptimal for adoptive T-cell therapy (ATT).
106 of the AML patients receiving adoptive NK-92 cell therapy block anti-leukemia cytotoxicity of NK-92 c
107          Emerging technologies--such as stem cell therapy, bone anabolic agents, genetic approaches,
108   The disease is a potential target for stem cell therapy but success is likely to be limited by the
109 ciated self-antigens that are amenable for T-cell therapy, but also allows TCR targeting of the cance
110 molysis bullosa treated with allogeneic stem cell therapy, but with little success.
111 nt cells may contribute to the efficacy of T-cell therapy by maintaining effector function and promot
112                                              Cell therapies can be also delivered intratumorally, inc
113                                           NK cell therapy can be further improved by optimal donor se
114         Thus, application of optogenetics in cell therapy can link transplantation, animal behavior a
115 nized early and treated with targeted plasma cell therapy, can be managed very effectively.
116 nic stimulation in tumors and after adoptive cell therapy, CD8 TCR signaling and Nur77GFP induction i
117   Application of miR-146b combined with stem cell therapy could enhance regeneration of cartilaginous
118      Umbilical cord-mesenchymal stem/stromal cell therapy decreased nicotinamide adenine dinucleotide
119                      The efficacy of cardiac cell therapy depends on the integration of existing and
120 nts with fistulizing CD, mesenchymal stromal cell therapy deposits MSCs locally, into fistulizing tra
121 trategies to increase PCs and exogenous stem cell therapies designed to improve regenerative capacity
122                         We found that anti-B cell therapy did not alter the frequencies of autoreacti
123  therapeutic agents as well as vaccine and T-cell therapies directed at mesothelin are undergoing cli
124 were randomly assigned to receive autologous cell therapy (endothelial cells, n = 4) or control treat
125                                              Cells therapies, engineered to secrete replacement prote
126 cted organ damage and deaths following CAR T-cell therapy first highlighted the possible dangers of t
127 nical ventilation a median of 6 days after T cell therapy; five met criteria for acute respiratory di
128                   Assessing the retention of cell therapies following implantation is vital and often
129 ance the efficacy of vaccines and adoptive T cell therapies for cancer and infectious diseases or, co
130 nalyses have recently arisen in the field of cell therapies for cardiovascular repair and regeneratio
131 espite encouraging preliminary results, stem cell therapies for patients with CHD should only be cons
132 o Food and Drug Administration-approved stem cell therapies for retinal disease exist.
133 nt clinical translation of neural progenitor cell therapy for ALS.
134 success of chimeric antigen receptor (CAR) T cell therapy for B cell malignancies represents a paradi
135                         Recent advances in T-cell therapy for cancer, viral infections, and autoimmun
136     Conclusions and Relevance: Although stem cell therapy for cardiovascular disease is not yet ready
137 be used to advance development of adoptive T-cell therapy for HCC.
138 evaluating safety and efficacy of autologous cell therapy for intractable peripheral arterial disease
139                    Autologous and allogeneic cell therapy for ischemic heart disease show a similar i
140 the effectiveness of cardiac stem/progenitor cell therapy for ischemic heart disease.
141               In a mouse model of adoptive T cell therapy for melanoma, Runx3-deficient CD8(+) tumour
142 t challenge for the continued development of cell therapy for Parkinson's disease (PD) is the establi
143 rategies to augment the feasibility of CAR T-cell therapy for patients with AML.
144 rome occurred in 46% of patients following T cell therapy for relapsed/refractory acute lymphoblastic
145 ss with chimeric antigen receptor-modified T cell therapy for relapsed/refractory acute lymphoblastic
146  system development and serve as a potential cell therapy for SCI.
147  potential as an autologous, multifunctional cell therapy for stroke, which is the primary cause of l
148 ed CD40L, and the potential for its use in T-cell therapy for X-HIGM syndrome.
149  bronchoalveolar lavage were reduced in both cell therapy groups, despite a reduction in bronchoalveo
150 s the gold standard treatment modality, stem cell therapy has been gaining ground as a complimentary
151 c antigen receptor (CAR)-modified adoptive T-cell therapy has been successfully applied to the treatm
152 regenerative medicine mediated by adult stem cell therapy has gathered momentum fueled by tantalizing
153                              RATIONALE: Stem cell therapy has increased the therapeutic armamentarium
154          Chimeric antigen receptor T (CAR-T) cell therapy has produced impressive results in clinical
155                                         Stem cell therapy has recently emerged as a promising method
156            Chimeric antigen receptor (CAR) T cell therapy has shown limited efficacy for the manageme
157                         Recently, adoptive T-cell therapy has shown salvage responses in multiple ref
158                                   Adoptive T cell therapy has shown significant clinical success for
159                                 Cardiac stem cell therapy has shown very promising potential to repai
160 y no longer be guaranteed because autologous cell therapy has the potential to modify the natural his
161   Treatment of cancer patients by adoptive T cell therapy has yielded promising results.
162                                   Adoptive T cell therapies have achieved significant clinical respon
163                           Current progenitor cell therapies have only modest efficacy, which has limi
164                                     Gene and cell therapies have the potential to prevent, halt, or r
165 ansplantation (HSCT) and mesenchymal stromal cell therapy have been proposed for patients with refrac
166 m cell therapies and to overcome issues with cell therapy have been used with varied success.
167  marrow transplantation and mesenchymal stem cell therapy, have entered into early clinical trials.
168 splanting autologous beta-cells for diabetes cell therapy, highlighting the unique advantages and cha
169                          Although adoptive T-cell therapy holds promise for the treatment of many can
170 ne marrow by flow cytometry after CD19 CAR-T-cell therapy; however, within 1 month of CAR-T-cell infu
171 tions for the development of effective CAR T cell therapies in cancer patients.
172 he safety and efficacy of different types of cell therapies in patients with ischemic stroke.
173 ed catheter-directed delivery of endothelial cell therapy in a porcine model of cirrhosis for liver r
174 itioned medium (CM-MSC) as an alternative to cell therapy in an antigen-induced model of arthritis (A
175 ndation of cellular engineering for adoptive cell therapy in cancer and other diseases.
176 ication of chimeric antigen receptor (CAR) T cell therapy in cancers.
177 SC-based strategies for disease modeling and cell therapy in CNS disorders.
178 ys for beta-cell generation is essential for cell therapy in diabetes.
179 rolled preclinical trials of unmodified stem cell therapy in large animal models of myocardial ischem
180  melanoma antigens before and after adoptive cell therapy in melanoma patients, we observe a greater
181 ch are of the greatest interest for adoptive cell therapy in patients with cancer.
182 riers to the clinical implementation of stem cell therapy in patients with cardiovascular disease and
183 rs facing the routine implementation of stem cell therapy in patients with cardiovascular disease is
184 chimeric antigen receptor-modified T (CAR-T) cell therapy in patients with chronic lymphocytic leukem
185 d transendocardial injection of ixmyelocel-T cell therapy in patients with heart failure and reduced
186 ently being examined in clinical trials as T cell therapy in patients with inflammatory bowel disease
187 cells (MSC) have become a promising tool for cell therapy in regenerative medicine.
188 n approach for improving mesenchymal stromal cell therapy in scleroderma and other diseases.
189 vices may improve the effectiveness of CAR T cell therapy in solid tumors and help protect against th
190 e considered during the design of adoptive T cell therapies, including use of engineered T cells.
191              We review key achievements in T-cell therapy, including the use of recombinant immune re
192  replacement, autologous and allogeneic stem cell therapy, innovations in cancer biology, revertant m
193 well as the unaddressed integration of CAR T-cell therapy into conventional anticancer treatments.
194             Future peripheral artery disease cell therapy investigational trial design may be informe
195          The design, and manufacturing, of T cell therapies is not standardized and is performed most
196      ABSTRACT: Autologous cardiac progenitor cell therapy is a promising alternative approach to curr
197    CD4(+)CD25(+)Foxp3(+) regulatory T (Treg) cell therapy is a promising approach for the treatment o
198                             Importance: Stem cell therapy is a promising treatment strategy for patie
199            Chimeric antigen receptor (CAR) T-cell therapy is an emerging immunotherapy against severa
200                         Refinement of this T-cell therapy is crucial to improve the frequency of clin
201         An innovative microneedle (MN)-based cell therapy is developed for glucose-responsive regulat
202                              Adoptive immune cell therapy is emerging as a promising immunotherapy fo
203  Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is highly promising but requires robust T-c
204 y, the general application of current CAR-T--cell therapy is limited by serious treatment-related tox
205 in solid tumors, the full potential of CAR T cell therapy is limited by the availability of cell surf
206 Despite important achievements to date, stem cell therapy is not yet ready for routine clinical imple
207 small-scale studies have suggested that stem-cell therapy is safe and effective in patients with live
208 nd beta-cells is crucial for developing stem cell therapies, islet regeneration strategies, and thera
209  when generating T-cell lines for adoptive T-cell therapy, it avoids the loss of those clones, which
210 r drug targeting, gene delivery, cancer stem cell therapy, magnetic drug targeting and ultrasound-med
211 se strategies could help overcome unresolved cell therapy manufacturing challenges and complement fra
212 boratories, clinical diagnostics assays, and cell therapy manufacturing.
213                         The recognition that cell therapy may be cardioprotective, and not just regen
214 able strategy to improve anti-tumor adoptive cell therapy may be to engineer tumor-restricted T cells
215 al studies; it suggests that the benefits of cell therapy may be underestimated or even overlooked if
216 tion of fetal neural precursors suggest that cell therapy may offer a cure for this devastating neuro
217                      We conclude that anti-B cell therapy may provide a temporary dampening of autoim
218 of low survivability in current cardiac stem cell therapies, mechanical and metabolic, were explored.
219  of regenerating appropriate connections for cell therapy.Midbrain dopaminergic neurons (mDAs) in the
220 ods to define dose and pharmacokinetics of T cell therapies need to be developed.
221 progenitor cells (hBTSCs) are being used for cell therapies of patients with liver cirrhosis.
222  that FRbeta is a promising target for CAR T-cell therapy of AML, which may be augmented by combinati
223                                     Adoptive cell therapy of chronic lymphocytic leukemia (CLL) with
224 g cells (ECFCs) are promising candidates for cell therapy of ischemic diseases, as less than 10% of p
225 tention and animal survival for in vivo stem cell therapy of myocardial infarction.
226 romoting cell engraftment and thus improving cell therapy of the infarcted myocardium.
227                           BACKGROUND & AIMS: Cell therapy offers the potential to treat gastrointesti
228 ed with chimeric antigen receptor-modified T cell therapy on a phase I/IIa clinical trial.
229                      Remarkably, efficacy of cell therapy on all end points was no longer significant
230 ndividual patient data reported no effect of cell therapy on left ventricular function or clinical ou
231                                 No effect of cell therapy on major adverse cardiac and cerebrovascula
232                                         Stem cell therapy once held promise for generating large quan
233 cise changes to gene expression for gene and cell therapies or fundamental studies of gene function.
234          Intraportal delivery of endothelial cell therapy or saline was technically successful in all
235    The Pulmonary Hypertension and Angiogenic Cell Therapy (PHACeT) trial was a phase 1, dose-escalati
236   Mechanisms of regulatory B cells and their cell therapy potential are important to decipher in expe
237 cells are a bone marrow-derived, allogeneic, cell therapy product that modulates the immune system, a
238 sed as a reference for characterizing future cell therapy products destined to treat endothelial dysf
239 shelf, genetically enhanced, histocompatible cell therapy products.
240       Undoubtedly, as insulin producing stem cell therapies progress, a transplant site that is retri
241                                         Stem cell therapy provides immense hope for regenerating the
242 ll randomized controlled trials) showed that cell therapy reduced the risk of amputation by 37%, impr
243 sruption of inhibitory checkpoints and CAR T cell therapy remains incompletely explored.
244 int blockade and chimeric antigen receptor T cell therapies represent a turning point in cancer immun
245                                         Stem cell therapy represents a promising strategy in regenera
246          Further development of engineered T cell therapies requires advances in immunology, syntheti
247                               Development of cell therapy requires a better understanding of the sign
248                                   However, T cell therapy requires efficient generation of the select
249                     Further development of T cell therapy requires improved strategies to select effe
250 y enrolled in the CCTRN TIME (Cardiovascular Cell Therapy Research Network Timing in Myocardial Infar
251 t protein inhibition, vaccines, and adoptive cell therapy seem to activate more specific T cells that
252               Swine treated with endothelial cell therapy showed mean levels of surrogate markers of
253  anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, showed efficacy in patients with refractor
254                                              Cell therapy significantly increased ankle brachial inde
255 SCs) are ideal cell sources for personalized cell therapies since they can be expanded to generate la
256  fusion and nuclear reprogramming may aid in cell therapy strategies for skeletal muscle diseases.
257 ring these cells ex vivo and using them in T-cell therapy strategies.
258 to the AML-NK dysfunction and a potential NK cell therapy strategy.
259 eir families and discussing participation in cell therapy studies are described, including participat
260                         Informed consent for cell therapy studies in patients with stroke requires le
261 o the modest functional benefits observed in cell-therapy studies by regulating the amount of contrac
262  of our knowledge, ixCELL-DCM is the largest cell therapy study done in patients with heart failure s
263 her alone or used in, combination with other cell therapies (such as hematopoietic stem cells or bone
264                   Some early-phase trials of cell therapies suggest acceptable safety profiles.
265 al framework for the development of targeted cell therapies that can be customized to any clinical ap
266 ssociated with low levels of autoimmunity to cell therapies that can induce damaging cross-reactivity
267                              CCs are a novel cell therapy that improves on combinatorial cell approac
268 wever, it remains largely unknown how anti-B cell therapy thwarts autoimmunity in these pathologies.
269 anslational therapeutic strategies including cell therapy, tissue engineering, and regenerative medic
270 e safety and efficacy of mesenchymal stromal cell therapies to allow the translation of this research
271                   However, gene, protein and cell therapies to increase microvascularization have not
272 sequently, TECs are an attractive target for cell therapies to restore effective immune system functi
273 ategies to improve and tailor Treg cells for cell therapy to induce transplantation tolerance are hig
274 lecules may expand the scope of engineered T-cell therapy to solid tumors, as well as indications bey
275 used human TR1 cells, currently employed for cell therapy, to confirm our results.
276 used to enhance vaccine efficacy or adoptive cell therapy treatments that target cancer.
277 cardial Infarction Evaluation) was the first cell therapy trial sufficiently powered to determine if
278 s for recruitment of patients with stroke in cell therapy trials is complex and requires extensive di
279    This study summarizes the use of adoptive cell therapy, tumor vaccines, immune checkpoint inhibito
280  hematologic complete remission (CR) after T-cell therapy, upon emergence of (p190)BCR-ABL-specific T
281                                 Importantly, cell therapies using IRE1alpha-expressing BMPCs or direc
282  safety and efficacy of an adoptive CD4(+) T-cell therapy using an MHC class II-restricted, HLA-DPB1*
283                   RATIONALE: Autologous stem cell therapy using human c-Kit(+) cardiac progenitor cel
284 rapy, and an optimal approach for hMSC-based cell therapy using non-viral vectors has not been establ
285                                              Cell therapy was also found to improve liver glycogen st
286                                  Response to cell therapy was defined by changes in left ventricular
287                                              Cell therapy was not associated with severe adverse even
288 rd decreased liver fibrosis with endothelial cell therapy was observed.
289                    Transendocardial CD133(+) cell therapy was safe.
290                                        After cell therapy, we found a temporary (15 weeks) decrease i
291 on in low-contamination applications such as cell therapies, where good manufacturing practice compat
292 fficacy of chimeric antigen receptor (CAR) T cell therapies, which redirect T cells to solid tumors.
293 oint toward a future when antigen-specific T-cell therapies will play a central role in alloHSCT.
294  in future studies aimed at developing liver cell therapies with lab-made hepatocytes.
295 rvival significantly enhanced after adoptive cell therapy with agonist OX40 immunotherapy.
296 imaging-guided catheter-directed endothelial cell therapy with an intraportal technique for the treat
297 ory large B-cell lymphoma who received CAR T-cell therapy with axi-cel had high levels of durable res
298  function in animal models of heart failure; cell therapy, with autologous bone marrow derived mononu
299  that a combination of alpha-4-1BB and CAR T-cell therapy would result in improved antitumor response
300 ration, and differentiation of cells in stem cell therapies, wound healing, and the treatment of canc

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。
 
Page Top